Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Our lead candidate PIKTOR is an all-oral combination that is designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously.
Calendar
–
View all events & presentations
Events.
Oct
06
2026
Virtual KOL Event: Multi-Nodal Inhibition for the Treatment of Endometrial Cancer
Latest
–
View all news
News and updates.
Oct 19 2026
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer Poster also includes results from head-to-head comparisons with gedatolisib, another multi-nodal inhibitor of the PI3K-AKT-mTOR
Read More
Sep 17 2026
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
Renowned cancer biologist and Faeth scientific co-founder joins the Board as the Company approaches topline Phase 2 data for PIKTOR in endometrial cancer AUSTIN, Texas --(BUSINESS WIRE)--Sep. 17, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on
Read More
Sep 08 2026
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
AUSTIN, Texas --(BUSINESS WIRE)--Sep. 8, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October
Read More
Sep 01 2026
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
AUSTIN, Texas --(BUSINESS WIRE)--Sep. 1, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor
Read More
Aug 28 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas --(BUSINESS WIRE)--Aug. 28, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company’s common stock in connection with their
Read More